Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free SBTX Stock Alerts

SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics logo
GBX 10 -0.25 (-2.44%)
As of 07:18 AM Eastern
Compare

SBTX vs. TILS, VSN, SCLP, MPH, and FARN

Should you buy SkinBioTherapeutics stock or one of its competitors? SkinBioTherapeutics's main competitors and comparable companies include Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and Faron Pharmaceuticals Oy (FARN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SkinBioTherapeutics compare to Tiziana Life Sciences?

SkinBioTherapeutics (LON:SBTX) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Tiziana Life Sciences has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M4.96-£3.71M-£0.16N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

Tiziana Life Sciences has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Tiziana Life Sciences' return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Tiziana Life Sciences N/A N/A N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for Tiziana Life Sciences and 0 mentions for SkinBioTherapeutics. Tiziana Life Sciences' average media sentiment score of 1.33 beat SkinBioTherapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Tiziana Life Sciences Positive

3.0% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tiziana Life Sciences beats SkinBioTherapeutics on 6 of the 10 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Verseon?

SkinBioTherapeutics (LON:SBTX) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

3.0% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Verseon has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Verseon's return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Verseon N/A N/A N/A

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Verseon Neutral

Verseon has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M4.96-£3.71M-£0.16N/A
VerseonN/AN/AN/A-£14.30N/A

Summary

SkinBioTherapeutics and Verseon tied by winning 4 of the 8 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Scancell?

Scancell (LON:SCLP) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

1.5% of Scancell shares are owned by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are owned by institutional investors. 15.5% of Scancell shares are owned by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

SkinBioTherapeutics has higher revenue and earnings than Scancell. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Scancell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scancell£4.71M21.37-£6.75M-£0.55N/A
SkinBioTherapeutics£5.23M4.96-£3.71M-£0.16N/A

In the previous week, Scancell's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Scancell Neutral
SkinBioTherapeutics Neutral

Scancell has a beta of 0.687, indicating that its stock price is 31% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.107, indicating that its stock price is 89% less volatile than the broader market.

SkinBioTherapeutics has a net margin of -8.73% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 90.29% -45.28%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Summary

Scancell beats SkinBioTherapeutics on 6 of the 11 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Mereo BioPharma Group plc (MPH.L)?

SkinBioTherapeutics (LON:SBTX) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Mereo BioPharma Group plc (MPH.L) has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M4.96-£3.71M-£0.16N/A
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A

In the previous week, Mereo BioPharma Group plc (MPH.L) had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for Mereo BioPharma Group plc (MPH.L) and 0 mentions for SkinBioTherapeutics. Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.13 beat SkinBioTherapeutics' score of 0.00 indicating that Mereo BioPharma Group plc (MPH.L) is being referred to more favorably in the news media.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Mereo BioPharma Group plc (MPH.L) Neutral

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Mereo BioPharma Group plc (MPH.L) N/A N/A N/A

3.0% of SkinBioTherapeutics shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Mereo BioPharma Group plc (MPH.L) beats SkinBioTherapeutics on 6 of the 10 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Faron Pharmaceuticals Oy?

SkinBioTherapeutics (LON:SBTX) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

SkinBioTherapeutics has a beta of 0.107, meaning that its share price is 89% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.121, meaning that its share price is 12% more volatile than the broader market.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Faron Pharmaceuticals Oy N/A 45.13%-70.00%

SkinBioTherapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M4.96-£3.71M-£0.16N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

3.0% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Faron Pharmaceuticals Oy Neutral

Summary

SkinBioTherapeutics and Faron Pharmaceuticals Oy tied by winning 5 of the 10 factors compared between the two stocks.

Get SkinBioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

Export
MetricSkinBioTherapeuticsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£25.92M£3.74B£7.08B£2.89B
Dividend YieldN/A3.76%2.58%6.09%
P/E Ratio-62.5010.36268.54368.57
Price / Sales4.961,270.17651.2083,659.40
Price / Cash9.00102.9470.5927.89
Price / Book5.9617.8113.117.22
Net Income-£3.71M-£13.23M£3.45B£5.89B
7 Day Performance-13.04%2.97%1.81%1.34%
1 Month Performance4.43%1.40%0.90%2.83%
1 Year Performance-34.59%55.32%67.67%70.18%

SkinBioTherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
SkinBioTherapeutics
N/AGBX 10
-2.4%		N/A-32.5%£25.92M£5.23MN/A11
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
SCLP
Scancell
N/AGBX 9.45
-0.5%		N/A-9.3%£101.44M£4.71MN/A51
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SBTX) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel